<DOC>
	<DOCNO>NCT01644396</DOCNO>
	<brief_summary>This open-label study design establish safety effectiveness adalimumab treatment moderate severe plaque psoriasis 24 week treatment .</brief_summary>
	<brief_title>An Open-Label , Prospective Study Assess Safety Effectiveness Adalimumab Patients With Moderate Severe Plaque Psoriasis Russian Federation</brief_title>
	<detailed_description>During treatment period , participant receive initial adalimumab 80 milligram ( mg ) subcutaneous ( sc ) dose , follow adalimumab 40 mg sc every week start one week initial dose . Safety effectiveness assessment complete Baseline , Week 2 , Week 4 , Week 8 , Week 12 , Week 16 Week 24 . Participants may discontinue adalimumab treatment time study participation . Participants end study participation early Premature Discontinuation visit . All participant initiate commercial Humira® follow-up phone call 70 day last administration study drug obtain information new ongoing Adverse Events ( AEs ) . The 70-day follow-up phone call require participant initiate adalimumab therapy supply context clinical trial end study participation .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>A patient eligible study participation he/she meet follow criterion : 1 . Male female patient ≥ 18 year age . 2 . Clinical diagnosis psoriasis least 6 month determine patient interview his/her medical history confirmation diagnosis physical examination investigator . 3 . Stable plaque psoriasis least 2 month Screening Baseline visit determine patient interview his/her medical history . 4 . Moderate severe plaque psoriasis define ≥ 10 % Body Surface Area ( BSA ) involvement Baseline visit . 5 . PASI ( Psoriasis Area Severity Index ) score ≥ 10 Baseline visit . 1 . Diagnosis erythrodermic psoriasis , pustular psoriasis , medication induce medicationexacerbated psoriasis new onset guttate psoriasis . 2 . Diagnosis active skin disease skin infection ( bacterial , fungal , viral ) may interfere evaluation psoriasis . 3 . Patient discontinue topical therapy treatment psoriasis corticosteroid , vitamin D analog , retinoids least 14 day prior Baseline ( Week 0 ) visit study . Participants allow use : Shampoos contain corticosteroid ; Bland ( without beta alpha hydroxy acid contain psoriasis treatment ) emollient ; Low potency topical corticosteroid palm , sol , face , inframammary area , groin . 4 . Patient avoid UVB ( UltravioletB ) phototherapy least 14 day prior Baseline ( Week 0 ) visit study . 5 . Patient avoid PUVA ( psoralen + ultraviolet A ) phototherapy least 28 day prior Baseline ( Week 0 ) visit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Moderate Severe Plaque Psoriasis</keyword>
</DOC>